Health · 48 views
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5…
AI Summary
An investigational EGFR × HER3 antibody‑drug conjugate showed promising efficacy and a tolerable safety profile in patients with previously treated EGFR‑mutated non‑small cell lung cancer, leading researchers to select a 2.5 mg/kg dose for the global Phase III IZABRIGHT‑Lung01 registrational study.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Smoke from LA fires exposed millions of people to high levels of toxic heavy metals, study saysContinue reading
- CDC names the 4 most dangerous superbugs in the USContinue reading
- Rare Brain Disorder Linked to Water Pollution SourcesContinue reading
- Biological mechanism underlying Huntington's disease may be more widespread in the brain than previously thoughtContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow